BeiGene, Ltd. (NASDAQ: ONC) — Company Overview, News & Financial Data
BeiGene, Ltd.
ONC BeiGene, Ltd.
Company profile
BeiGene, Ltd.
BeiGene, Ltd. is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing targeted therapies and immunotherapies for cancer treatment. The company advances a broad clinical pipeline of small molecule inhibitors, monoclonal antibodies, and bispecific antibodies aimed at addressing hematologic malignancies and solid tumors worldwide. Operating across North America, Europe, Asia-Pacific, and other international regions, the organization conducts research, clinical trials, and commercial operations to improve therapeutic access and outcomes for oncology patients.
Snapshot
Public USOwnership
2010Year founded
~12,000Employees
Basel, SwitzerlandHead office
Loading Map...
Global footprint
Operations
Products and/or services of BeiGene, Ltd.
- Bruton Tyrosine Kinase Inhibitors: Small molecule kinase inhibitors designed to block signals required for B-cell proliferation and survival, indicated for treating chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom macroglobulinemia globally.
- PD-1 Immune Checkpoint Inhibitors: Humanized IgG4 monoclonal antibodies directed against programmed cell death protein 1, developed to restore anti-tumor immune response in esophageal, gastric, and non-small cell lung cancers across international markets.
- HER2 Bispecific Antibodies: Dual HER2-targeted bispecific antibodies engineered to bind distinct domains of the HER2 receptor, inhibiting cell signaling and mediating tumor cell death in HER2-expressing gastrointestinal and biliary tract cancers.
- Chimeric Degradation Activating Compounds: Targeted protein degradation platform therapies engineered to selectively destroy disease-causing target proteins, including novel next-generation BTK degraders for hematologic malignancies resistant to standard targeted inhibitor treatments.
- Antibody-Drug Conjugates: Monoclonal antibodies chemically conjugated to potent cytotoxic payloads designed to selectively deliver therapeutic agents directly to target tumor cells expressing specific surface antigens across thoracic, gynecological, and gastrointestinal cancers.
- Biopharmaceutical Manufacturing and Supply: Global commercial and clinical-scale production operations encompassing small-molecule chemical synthesis, large-molecule biologics manufacturing, secondary packaging, and supply chain management across specialized facilities in North America, Europe, and Asia.
BeiGene, Ltd. executive team
- Mr. John V. OylerCo-Founder, Executive Chairman & CEO
- Mr. Wang Lai Ph.D.President and Global Head of Research & Development
- Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
- Mr. Aaron RosenbergChief Financial Officer
- Mr. Chan LeeGeneral Counsel & Senior VP
- Mr. Titus B. BallVP & Chief Accounting Officer
- Mr. Marcello DamianiChief Technology Officer
- Ms. Liza HeapesHead of Investor Relations
- Ms. Eleanor Duff Ph.D.Senior VP & Head of Corporate Communications
- Dr. Mark LanasaSenior VP & Chief Medical Officer for Solid Tumors